611 related articles for article (PubMed ID: 32921673)
1. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
Matsui H; Kawai T; Sato Y; Ishida J; Kadowaki H; Akiyama Y; Yamada Y; Nakamura M; Yamada D; Akazawa H; Suzuki M; Komuro I; Kume H
Int Heart J; 2020 Sep; 61(5):1070-1074. PubMed ID: 32921673
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab-induced myocarditis with complete atrioventricular block and concomitant myositis in a metastatic bladder cancer patient: a case report and review of the literature.
Saad R; Ghaddar A; Zeenny RM
J Med Case Rep; 2024 Feb; 18(1):107. PubMed ID: 38383436
[TBL] [Abstract][Full Text] [Related]
3. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.
Monge C; Maeng H; Brofferio A; Apolo AB; Sathya B; Arai AE; Gulley JL; Bilusic M
J Immunother Cancer; 2018 Dec; 6(1):150. PubMed ID: 30563577
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab and epacadostat induced fatal myocarditis and myositis presenting as a case of ptosis and ophthalmoplegia.
Hellman JB; Traynis I; Lin LK
Orbit; 2019 Jun; 38(3):244-247. PubMed ID: 29985683
[TBL] [Abstract][Full Text] [Related]
5. [Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].
Ying YC; Tang Q; Yang KW; Mi Y; Fan Y; Yu W; Song Y; He ZS; Zhou LQ; Li XS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):644-651. PubMed ID: 35950386
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report.
Kamo H; Hatano T; Kanai K; Aoki N; Kamiyama D; Yokoyama K; Takanashi M; Yamashita Y; Shimo Y; Hattori N
BMC Neurol; 2019 Aug; 19(1):184. PubMed ID: 31382909
[TBL] [Abstract][Full Text] [Related]
7. Fulminant Myocarditis Caused by an Immune Checkpoint Inhibitor: A Case Report With Pathologic Findings.
Imai R; Ono M; Nishimura N; Suzuki K; Komiyama N; Tamura T
J Thorac Oncol; 2019 Feb; 14(2):e36-e38. PubMed ID: 30391574
[No Abstract] [Full Text] [Related]
8. Pembrolizumab-Induced Fatal Myasthenia, Myocarditis, and Myositis in a Patient with Metastatic Melanoma: Autopsy, Histological, and Immunohistochemical Findings-A Case Report and Literature Review.
Giovannini E; Bonasoni MP; D'Aleo M; Tamagnini I; Tudini M; Fais P; Pelotti S
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446095
[TBL] [Abstract][Full Text] [Related]
9. Asymptomatic Myocarditis with Mild Cardiac Marker Elevation Following Nivolumab-Induced Myositis.
Shindo A; Yamasaki M; Uchino K; Yamasaki M
Int Heart J; 2022; 63(1):180-183. PubMed ID: 35095069
[TBL] [Abstract][Full Text] [Related]
10. Atezolizumab-induced myositis and myocarditis in a patient with metastatic urothelial carcinoma.
Sessums M; Yarrarapu S; Guru PK; Sanghavi DK
BMJ Case Rep; 2020 Dec; 13(12):. PubMed ID: 33298477
[TBL] [Abstract][Full Text] [Related]
11. Myositis as an adverse event of immune checkpoint blockade for cancer therapy.
Shah M; Tayar JH; Abdel-Wahab N; Suarez-Almazor ME
Semin Arthritis Rheum; 2019 Feb; 48(4):736-740. PubMed ID: 29909921
[TBL] [Abstract][Full Text] [Related]
12.
Boughdad S; Latifyan S; Fenwick C; Bouchaab H; Suffiotti M; Moslehi JJ; Salem JE; Schaefer N; Nicod-Lalonde M; Costes J; Perreau M; Michielin O; Peters S; Prior JO; Obeid M
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34686542
[TBL] [Abstract][Full Text] [Related]
13. New drugs and new toxicities: pembrolizumab-induced myocarditis.
Inayat F; Masab M; Gupta S; Ullah W
BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29367376
[TBL] [Abstract][Full Text] [Related]
14. Case Report: Glucocorticoid Effect Observation in a Ureteral Urothelial Cancer Patient With ICI-Associated Myocarditis and Multiple Organ Injuries.
Hu X; Wei Y; Shuai X
Front Immunol; 2021; 12():799077. PubMed ID: 34975911
[TBL] [Abstract][Full Text] [Related]
15. Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring.
Katsume Y; Isawa T; Toi Y; Fukuda R; Kondo Y; Sugawara S; Ootomo T
Intern Med; 2018 Nov; 57(21):3157-3162. PubMed ID: 29877257
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer.
Touat M; Maisonobe T; Knauss S; Ben Hadj Salem O; Hervier B; Auré K; Szwebel TA; Kramkimel N; Lethrosne C; Bruch JF; Laly P; Cadranel J; Weiss N; Béhin A; Allenbach Y; Benveniste O; Lenglet T; Psimaras D; Stenzel W; Léonard-Louis S
Neurology; 2018 Sep; 91(10):e985-e994. PubMed ID: 30089619
[TBL] [Abstract][Full Text] [Related]
17. [A case of myasthenia gravis and myositis induced by pembrolizumab].
Noda T; Kageyama H; Miura M; Tamura T; Ito H
Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitor-Related Myositis Overlapping With Myocarditis: An Institutional Case Series and a Systematic Review of Literature.
Nakagomi Y; Tajiri K; Shimada S; Li S; Inoue K; Murakata Y; Murata M; Sakai S; Sato K; Ieda M
Front Pharmacol; 2022; 13():884776. PubMed ID: 35645839
[No Abstract] [Full Text] [Related]
19. Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature Review.
Kadota H; Gono T; Shirai Y; Okazaki Y; Takeno M; Kuwana M
Curr Rheumatol Rep; 2019 Feb; 21(4):10. PubMed ID: 30790071
[TBL] [Abstract][Full Text] [Related]
20. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]